Efficacy Biomarker Investigation on Extensive Stage Small Cell Lung Cancer

Hunan Province Tumor Hospital

Status: Completed

Conditions: Extensive Stage Small Cell Lung Cancer

Treatments: Drug: First line EC/EP+Atezolizumab

Study type: Observational

Funder types: Other

Identifiers

NCT05055947

EXACTLY

Details and patient eligibility

About

The purpose of the trial is to find some biomarkers to predict the efficacy of Atezolizumab plus etoposide and platinum based chemotherapy as the first line treatment in extensive stage small cell lung cancer. Mainly observe the patient's progression free survival time after treatment.

Enrollment: 60 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 18， Extensive Stage Small Cell Lung Cancer Confirmed by Histopathology Treated with Atezolizumab plus Etoposide and Platinum Based Chemotherapy

Exclusion criteria

• Patients with contraindication of chemotherapy Pregnant or breast feeding women